Assessing the transition of COVID-19 burden towards the young population while vaccines are rolled out in China*. Issue 1 (31st December 2022)

• Record Type: Journal Article
• Authors: Cai, Jun; Yang, Juan; Deng, Xiaowei; Peng, Cheng; Chen, Xinhua; Wu, Qianhui; Liu, Hengcong; Zhang, Juanjuan; Zheng, Wen; Zou, Junyi; Zhao, Zeyao; Ajelli, Marco; Yu, Hongjie
• Is Part Of: Emerging microbes & infections. Volume 11:Issue 1(2022)
• Page Start: 1205
• Page End: 1214
• Publication Date: 2022-12-31
• Subjects: Novel coronavirus disease 2019 -- Delta variant -- vaccination -- transition of disease burden -- children -- China; Medical microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 616.9041
• DOI: 10.1080/22221751.2022.2063073
• Languages: English
• ISSNs: 2222-1751

Abstract

ABSTRACT: SARS-CoV-2 infection causes most cases of severe illness and fatality in older age groups. Over 92% of the Chinese population aged ≥12 years has been fully vaccinated against COVID-19 (albeit with vaccines developed against historical lineages). At the end of October 2021, the vaccination programme has been extended to children aged 3–11 years. Here, we aim to assess whether, in this vaccination landscape, the importation of Delta variant infections could shift COVID-19 burden from adults to children. We developed an age-structured susceptible-infectious-removed model of SARS-CoV-2 transmission to simulate epidemics triggered by the importation of Delta variant infections and project the age-specific incidence of SARS-CoV-2 infections, cases, hospitalizations, intensive care unit admissions, and deaths. In the context of the vaccination programme targeting individuals aged ≥12 years, and in the absence of non-pharmaceutical interventions, the importation of Delta variant infections could have led to widespread transmission and substantial disease burden in mainland China, even with vaccination coverage as high as 89% across the eligible age groups. Extending the vaccination roll-out to include children aged 3–11 years (as it was the case since the end of October 2021) is estimated to dramatically decrease the burden of symptomatic infections and hospitalizations within this age group (39% and 68%, respectively, when considering a vaccination coverage of 87%), but would have a low impact on protecting infants. Our findings highlight the importance of including children among the target population and the need to strengthen vaccination efforts by increasing vaccine effectiveness.